- Home
- NSTS vs BLRX Comparison
NSTS vs BLRX Comparison
Compare NSTS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- BLRX
- Stock Information
- Founded
- NSTS 1921
- BLRX 2003
- Country
- NSTS United States
- BLRX Israel
- Employees
- NSTS N/A
- BLRX N/A
- Industry
- NSTS Savings Institutions
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- BLRX Health Care
- Exchange
- NSTS Nasdaq
- BLRX Nasdaq
- Market Cap
- NSTS 59.9M
- BLRX 36.0M
- IPO Year
- NSTS N/A
- BLRX 2011
- Fundamental
- Price
- NSTS $11.89
- BLRX $0.20
- Analyst Decision
- NSTS
- BLRX Strong Buy
- Analyst Count
- NSTS 0
- BLRX 2
- Target Price
- NSTS N/A
- BLRX $5.50
- AVG Volume (30 Days)
- NSTS 7.6K
- BLRX 1.7M
- Earning Date
- NSTS 11-13-2024
- BLRX 11-25-2024
- Dividend Yield
- NSTS N/A
- BLRX N/A
- EPS Growth
- NSTS N/A
- BLRX N/A
- EPS
- NSTS N/A
- BLRX N/A
- Revenue
- NSTS $6,117,000.00
- BLRX $21,991,000.00
- Revenue This Year
- NSTS N/A
- BLRX N/A
- Revenue Next Year
- NSTS N/A
- BLRX N/A
- P/E Ratio
- NSTS N/A
- BLRX N/A
- Revenue Growth
- NSTS N/A
- BLRX N/A
- 52 Week Low
- NSTS $9.30
- BLRX $0.19
- 52 Week High
- NSTS $11.89
- BLRX $1.68
- Technical
- Relative Strength Index (RSI)
- NSTS 71.31
- BLRX 25.94
- Support Level
- NSTS $11.26
- BLRX $0.23
- Resistance Level
- NSTS $11.42
- BLRX $0.56
- Average True Range (ATR)
- NSTS 0.13
- BLRX 0.03
- MACD
- NSTS 0.03
- BLRX 0.00
- Stochastic Oscillator
- NSTS 100.00
- BLRX 11.82
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.